WAM
VBIV

Warberg Asset Management’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Warberg Asset Management’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-25,000
Closed -$16.7K – 260
2024
Q2 		$16.7K Buy
25,000
+10,000
+67% +$6.22K ﹤0.01% 166
2024
Q1 		$9.04K Hold
15,000
– – ﹤0.01% 166
2023
Q4 		$8.81K Hold
15,000
– – ﹤0.01% 173
2023
Q3 		$9.99K Buy
+15,000
New +$18.4K ﹤0.01% 176

Warberg Asset Management's VBIV Position: Q3 2024 in Review

Warberg Asset Management sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q3 2024, closing a stake of 25,000 shares — an estimated $16.7K sold.

Warberg Asset Management first reported a position in VBIV in Q3 2023 and held it in 4 quarters. The position peaked at $16.7K in Q2 2024. 1 fund tracked by Wall St. Rank holds VBIV as of Q3 2024.

  • Warberg Asset Management reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q3 2024 after selling out during the quarter.
  • Warberg Asset Management sold 25,000 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q3 2024, an estimated $16.7K.
  • Warberg Asset Management first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q3 2023 and held it in 4 quarters.
  • Warberg Asset Management's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $16.7K in Q2 2024.
  • 1 fund tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q3 2024.

Based on Warberg Asset Management's 13F filing for Q3 2024, filed 6 Nov 2024.